Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

BrUOG-BR-211B q3week Carboplatin With Weekly Abraxane and Trastuzumab As Neoadjuvant Therapy in Resectable and Unresectable HER2+ (Stage IIa-IIIb) Breast Cancer

NCT00617942 is registered in ClinicalTrials.gov with William Sikov MD as lead sponsor.

NCT NCT00617942
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00617942 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
BrUOG-BR-211B q3week Carboplatin With Weekly Abraxane and Trastuzumab As Neoadjuvant Therapy in Resectable and Unresectable HER2+ (Stage IIa-IIIb) Breast Cancer
Lead sponsor
William Sikov MD
Phase
Phase 2
Overall status
Completed
Start date
February 29, 2008
Completion date
December 31, 2015
Enrollment
60 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer